Elizabeth Klein quoted in Forbes healthcare article
The Forbes article takes a closer look at investing in the healthcare sector.
News
Autumn Statement Response
The Statement offered a vote of confidence and recognition of the crucial role EIS and VCT plays in stimulating the flow of capital to early -stage, high growth UK companies and driving greater overall economic expansion.
Arecor Receive Payment After Milestone Achieved
Arecor's ongoing progress from their licensed platform Arestat™ triggers milestone payment from Inhibrx Inc.
Laverock Therapeutics secures Innovate UK award
Laverock Therapeutics secures £1m funding via the Innovate UK Investor Partnerships Future Economy programme, supported by UKI2S
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial
Oxford BioTherapeutics's partner has dosed first patient in phase 2 trial that has potential to revolutionise treatment.
Wonderhood Studios: Channel 4 commissions second season of Super Surgeons: A Chance at Life
Wonderhood have been commissioned to produce a second season of Super Surgeons: A Chance at Life.
Laverock Therapeutics to demonstrate at the European Society of Gene & Cell Therapy
Laverock Therapeutics to demonstrate breadth of therapeutic applications of gene silencing platform at European Society of Gene & Cell Therapy.
Calculus Invests In Laverock Therapeutics
Calculus has led an investment round into Laverock Therapeutics, a company developing a unique gene silencing platform for the creation of programmable advanced therapies.
Wonderhood Studios To Become Lead Creative Agency At Coral
Wonderhood Studios continue their stellar performance of signing household names as clients as part of their advertising business.
Toronto Film Festival: Calculus Portfolio Companies Produce Films Among Top 20
Maven Screen Media and Brouhaha continue progress.
Scancell Announces Positive Data From The First Stage In Its Phase 2 SCOPE Trial with SCIB1 Cancer Vaccine
Scancell achieve significant milestone for their cancer vaccine.
Arecor’s Tetris Pharma Announces Agreement With Goodlife
Arecor's subsidiary Tetris Pharma have a signed an agreement with Goodlife.
Arecor To Collaborate With Top 10 Pharma
Arecor to partner with a Top 10 Pharma to develop an enhanced antibody formulation for one of its investigational drugs.
Spectral MD Receives Certification For Wound Imaging
Spectral MD has received certification to distribute and manufacture its DeepView wound imaging system.
Scancell’s cancer vaccine Modi-1 makes progress
Scancell's phase I ModiFY trial assessing its cancer vaccine Modi-1 in various difficult-to-treat cancer types makes progress following a positive safety review.
Wonderhood Commissioned For Park Lane Hilton Documentary
Wonderhood commissioned for a new documentary on the Park Lane Hilton, further exhibiting its exciting slate.
Calculus Q2 2023 Update
Calculus Q2 2023 Quarterly Update showcasing some great news stories from our portfolio companies.
Wonderhood’s ‘Evacuation’ premieres and receives 5 star reviews from critics
Wonderhood's latest production to premiere tells the tale of the British evacuation of Kabul in 2021 through military personnel's experiences.
Arecor Granted Key Patents In Europe and China
Arecor has a new level of protection for their proprietary insulin products in Europe and China.
Invizius announces ‘Angry Blood’ Haemodialysis Study and recruits its 300th patient
Invizius continues to advance their work improving the lives of people requiring dialysis.
Open Energy Market launches net zero Platform
True, a platform designed to help business with their Net Zero strategy.
Brouhaha’s latest production ‘Firebrand’ impresses at Cannes Film Festival
Brouhaha's latest project impresses at prestigious Cannes Film Festival.
Destiny Pharma announce very encouraging results in collaboration developing SporeGen’s SPOR-COV
This encouraging research programme stems from a collaboration Destiny Pharma has with SporeGen Limited
Brouhaha’s Firebrand part of Cannes film festival’s selection list
Brouhaha continue their progress with prestigious inclusion.